Generic Drugmakers Face An Increasingly Uncertain World: Moody’s

esilverman The forecast calls for pain. After a recent spate of judicial and regulatory decisions, generic drugmakers face higher legal, regulatory and insurance costs. And ...

Shire Launches Educational Resource for Diabetes

barbara.lempert Shire Launches Educational Resource for People Living with Diabetes and Their Caregivers HealTogether.com is designed to increase patient awareness of diabetic ...

Lundbeck Reports 2Q Loss

barbara.lempert New Products up 48%, Lundbeck raises expectations for 2013 Valby, Copenhagen, 7 August 2013 – H. Lundbeck A/S (Lundbeck) reports first half revenue of ...

EpiCept Reports Second Quarter 2013 Operating and Financial Results

barbara.lempert Special August 6 Stockholder Meeting to Approve Final Conditions to Merger with Immune Pharmaceuticals TARRYTOWN, N.Y., Aug. 1, 2013 /PRNewswire/ — EpiCept Corporation ...

Medicines Co. wraps $240M deal to buy ProFibrix following PhIII success

John Carroll FierceBiotech News

SIGA Selects Lead Candidate for Dengue Antiviral Program

barbara.lempert NEW YORK, Aug. 1, 2013 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (Nasdaq:SIGA) today announced that it has selected a lead candidate for its dengue fever antiviral ...

Analysts grow skeptical about Sanofi’s $800M bet on dengue vaccine

Ryan McBride Sanofi is betting an estimated $ 800 million for research and a new facility to produce an experimental vaccine for dengue–and not all analysts are giving the pharma ...

Hypermarcas leaps ahead in Brazil with surprise profits, sales surge

Tracy Staton Brazilian drugmaker Hypermarcas shows that market savvy pays, even when an economy hits the skids. Despite an unexpected lag in GDP growth, Hypermarcas posted a surprise ...

Opioid receptor could guide drug R&D on addiction

John Carroll Investigators from the Florida campus of the Scripps Research Institute have found that a compound that favors a certain biological pathway could provide scientists ...

The FDA OKs 5 blockbusters in slow start to 2013 drug approvals

John Carroll Few productivity metrics in biopharma measure up to the annual rate of new drug approvals. So now that the FDA has come through with only 13 novel approvals in the first ...

Compugen, Bayer in Potential $500M Deal

barbara.lempert Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies Compugen to hold 2nd Quarter Conference Call August ...

FDA Committee to Review COPD Drug

mia.burns Theravance Announces FDA Advisory Committee to Review ANORO(TM) ELLIPTA(TM) (UMEC/VI) for COPD SOUTH SAN FRANCISCO, CA — (Marketwired) — 08/01/13 –Theravance, ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS